USPTO Patent Applications - Therapeutics (A61P)

MPN Treatment Methods with Therapeutic Compounds

USPTO published patent application US20260097028A1 for therapeutic methods treating myeloproliferative neoplasms (MPN) including polycythemia vera, essential thrombocythemia, and myelofibrosis. The application covers combination therapies using compounds of Formula (I) or Formula (II) with JAK inhibitors, IDH inhibitors, PD-1/PD-L1/PD-L2 inhibitors, interferons, PI3K inhibitors, AKT inhibitors, mTOR inhibitors, or nucleoside analogs. Filed February 18, 2025, application number 19055807.

Cancer Treatment Patent Using Quinoline Derivative and Antibody

The USPTO published patent application US20260097030A1 on April 9, 2026, disclosing a therapeutic combination of a quinoline derivative and an antibody for treating cancer, specifically lung and liver tumors. The application names 14 inventors and was filed on April 11, 2025. This publication makes the application publicly available but does not grant any enforceable patent rights.

Anti-C5 Antibody, C5 iRNA Dosing Regimens, Complement Diseases

Anti-C5 Antibody, C5 iRNA Dosing Regimens, Complement Diseases

Immunogenic Compositions for SARS-CoV-2 Vaccines Using MHC Class II Peptides

USPTO published patent application US20260097115A1 for immunogenic compositions containing MHC class II-binding peptides derived from SARS-CoV-2 translation products. The application covers vaccine compositions and methods for treating and preventing COVID-19. Inventors include researchers from Broad Institute and affiliated institutions.

Novel Anti-Asporin Antibody Targets Fibrotic Disease Including Idiopathic Pulmonary Fibrosis

USPTO published patent application US20260098083A1 disclosing a novel antibody binding specifically to Asporin protein for predicting onset and treating fibrotic diseases, including idiopathic pulmonary fibrosis. Inventors are Hogeun Yoon and Soo-Yeon Park. The application was filed on September 20, 2023.

Anti-TMPRSS6 Monoclonal Antibodies and Therapeutic Uses

USPTO published patent application US20260098084A1 disclosing fully human anti-TMPRSS6 monoclonal antibodies for treating diseases associated with TMPRSS6. Inventors include Harvey Chin, Sarah J. Hatsell, Heinrich Emil Lob, Andrew J. Murphy, William Olson, Kei Saotome, and Bojie Zhang, with application number 19323318 filed September 9, 2025.

PD-1 Monoclonal Antibody Patent Application for Cancer Treatment

The USPTO published patent application US20260098092A1 for monoclonal antibodies targeting human programmed cell death protein 1 (PD-1) and methods for treating cancer using said antibodies and antigen-binding fragments. The application was filed October 4, 2023, naming seven inventors including Trairak Pisitkun and colleagues. Pharmaceutical and biotech companies developing PD-1/PD-L1 pathway cancer immunotherapies should monitor for this application's progression to grant.

US20260098093A1, VISTA Molecules, Cancer Treatment, 9th Apr

US20260098093A1, VISTA Molecules, Cancer Treatment, 9th Apr

Multispecific Antibodies Targeting HLA-A2/MAGE-A4 Cancer Therapy

USPTO published Roche/Genentech patent application US20260098095A1 disclosing multispecific antibodies binding to HLA-A2/MAGE-A4 complex for T cell activation in cancer treatment. The application covers antibody compositions, encoding polynucleotides, production methods, and therapeutic uses. The invention addresses immunotherapy approaches for HLA-A2-positive tumors expressing MAGE-A4 antigen.

Anti-CCR8 Antibodies Therapeutic Agents Patent Application

USPTO published patent application US20260098096A1 for anti-CCR8 antigen binding proteins and fragments for detection and therapy of various conditions, including cancer. The application was filed September 21, 2023, by inventor Remy Michel Robert. CCR8 is a G-protein coupled receptor implicated in tumor immunosuppression.

Immunotoxin-Based Targeted Therapy for Cancer, CCR4 Bispecific

The USPTO published patent application US20260098097A1 for methods of treating cancer using a genetically engineered C-C motif chemokine receptor 4 (CCR4) bispecific immunotoxin. The application, filed December 29, 2023, covers treatment of cutaneous T-cell lymphoma and other cancers via administration of the immunotoxin alone or in combination with additional therapeutic agents such as antibody-drug conjugates.

CCR8 Antibodies and Fusion Proteins for Cancer Treatment

The USPTO published patent application US20260098098A1 covering CCR8-binding antibodies and fusion proteins for cancer treatment. Inventors McGrath et al. filed Application No. 19182473 on April 17, 2025, with the application published on April 9, 2026. The patent covers therapeutic compositions and methods using CCR8-targeted biologics.

Glutathione Trisulfide Patent for Chemotherapy-Induced Neuropathy

Glutathione Trisulfide Patent for Chemotherapy-Induced Neuropathy

Pharmaceutical Composition Containing Mitochondria-Targeting Compound for Treating Macular Degeneration

The USPTO published patent application US20260097092A1 filed by Ulsan National Institute of Science and Technology for a pharmaceutical composition containing mitochondria-targeting compounds as active ingredients for treating macular degeneration and other retinal diseases. The application specifically covers compounds that induce apoptosis of senescent cells for prevention and treatment of aging-related diseases. The application was originally filed on January 11, 2023.

Targeted Amatoxin Conjugate for Treatment of Solid Tumors

Heidelberg Pharma Research GmbH has published a US patent application (US20260097093A1) for a targeted amatoxin-linker conjugate designed to treat solid tumors. The application discloses an amatoxin-linker construct where R1 and R2 are each OH, R3 is NH2 or a linker, R4 is H or a linker, and R5 is absent or O, with the conjugate useful in manufacturing binding moiety-toxin therapeutics. Filing date was October 6, 2025.

DBI Protein Modulation Methods for Autophagy and Metabolic Regulation

The USPTO published patent application US20260097094A1 disclosing methods for modulating diazepam binding inhibitor (DBI) protein activity to regulate autophagy and metabolic processes. The inventors demonstrate that DBI neutralization via monoclonal antibodies or active immunization induces autophagy, enhances starvation-induced weight loss, reduces food intake upon refeeding, and reduces weight gain from hypercaloric diets. The patent covers pharmaceutical compositions and therapeutic applications for metabolic disorders.

Pegylated Lipoprotein Nanoparticles Treat Neurodegenerative Diseases

The USPTO published patent application US20260097095A1 for pegylated reconstituted high-density lipoprotein nanoparticles designed to prevent or treat neurodegenerative diseases. The application, filed by inventors Lee, Kim, and Kim on October 10, 2025, was published on April 9, 2026.

4-1BBL AND IL-12 COMBINATION THERAPY FOR GLIOBLASTOMA

The USPTO published patent application US20260097096A1, a new intellectual property grant covering methods of treating glioblastoma using 4-1BBL administered via adeno-associated virus (AAV-F) in combination with recombinant IL-12 delivered by intratumoral injection. The patent names Koen Breyne, Xandra O. Breakefield, and Thorsten R. Mempel as inventors. Biotech and pharmaceutical companies developing cancer immunotherapies must monitor this IP landscape.

Painless NGF Compositions for Fracture Repair

The USPTO published patent application US20260097099A1 for painless nerve growth factor (NGF) compositions for bone fracture repair, filed by inventors Chelsea Bahney, Tejal Desai, Kevin Rivera, and Chengbiao Wu. The application covers pharmaceutical compositions comprising biomaterial carriers with painless NGF for stimulating bone fracture healing. Filing date was April 23, 2025.

PTGS2 Skin Disorders Carnosine Compound Treatment Method

USPTO published patent application US20260096978A1 disclosing a method for preventing, mitigating, or treating PTGS2-induced skin disorders using carnosine compounds of formula (I) applied to human skin. The application, filed November 14, 2022, names five inventors and covers cosmetic and dermatological formulations.

Ammonium Chloride Formulations for Viral Defense

The USPTO published patent application US20260097072A1 for ammonium chloride formulations designed to support human natural defense against viral infections. The invention claims compositions and methods using lysosomotropic agents, such as ammonium chloride (NH4Cl), to prevent viral uncoating within lysosomes of infected cells. The patent names Nikolaos Tsirikos-Karapanos and Nikolaos Drakoulis as inventors.

Engineered Immune Cells CAR-T CAR-NK BCMA TACI Cancer Therapy Patent Application

USPTO published patent application US20260097076A1 for engineered immune cells (T cells and NK cells) expressing chimeric antigen receptors targeting BCMA and/or TACI antigens for cancer therapy. The application discloses armored CAR-T and CAR-NK cells with enhanced features for tumor treatment. Filed September 20, 2023, by inventors Chen, Agrahari, Zhao, Nguyen, Zhang, Jiang, and O'Callaghan.

Pharmaceutical Composition Containing Neonatal Pig-Derived Mesenchymal Stem Cells for Treating Non-Porcine Animals

USPTO published patent application US20260097081A1 by Fukuoka University for a pharmaceutical composition containing neonatal pig-derived mesenchymal stem cells. The cells produce at least one humoral factor selected from TGF-β1, TGF-β2, VEGF-A, and VEGF-C for therapeutic use in treating cardiovascular conditions, wounds, and decubitus in non-porcine animals. The application was filed on October 10, 2025.

Human Hair Follicle-Derived Conditioned Media and Method of Making Same

USPTO published patent application US20260097082A1 covering methods for preparing hair follicle-derived conditioned media containing bioactive factors. The hair follicles are retrieved non-invasively and cultured to secrete therapeutic compounds. The application covers compositions for therapeutic and cosmetic treatments including hair restoration and skin repair.

Cbfβ-Expressing Vascular Smooth Muscle Cells for Age-Related Disease Treatment

The USPTO published patent application US20260097084A1 by Kyungpook National University Industry-Academic Cooperation Foundation covering a pharmaceutical composition containing Cbfβ-expressing vascular smooth muscle cells or culture fluid for preventing or treating age-related diseases. The invention demonstrates that Cbfβ expression in vascular smooth muscle cells inhibits osteoclast differentiation and prevents vascular calcification, offering potential therapeutic applications for conditions such as osteoporosis and age-related vascular disorders.

Heterotrophic Skin Bacteria Composition for Treating UV Damage and PLE

The USPTO published patent application US20260097086A1 by inventor Catherine O'Neill for a composition comprising heterotrophic skin bacteria or bacterial extract for modulating cytokine expression in skin cells. The composition is intended for preventing and treating skin damage caused by UV light and for treating polymorphous light eruption (PLE).

Markers for the Diagnosis of Biochemical Recurrence in Prostate Cancer

USPTO published patent application US20260092922A1 for biomarkers and diagnostic methods related to prostate cancer biochemical recurrence (BCR). The application (No. 19207308, filed May 13, 2025) includes 9 inventors and covers methods for detecting BCR biomarkers, compositions, and diagnostic kits. This is a routine patent publication with no new regulatory requirements.

TREM2 antibodies patent, neurodegenerative disease treatment, 2nd Apr

TREM2 antibodies patent, neurodegenerative disease treatment, 2nd Apr

Anti-CTLA-4 Antibodies for Treating Adenoid Cystic Carcinoma

The USPTO published patent application US20260092112A1 covering uses of anti-CTLA-4 antibodies for treating adenoid cystic carcinoma. Inventors Yang Liu and Pan Zheng filed Application No. 19112015 on September 15, 2023, with the application published April 2, 2026. The invention claims therapeutic applications of anti-CTLA-4 antibodies specifically for adenoid cystic carcinoma.

CD28/OX40 Bispecific Antibodies for Solid Organ Transplant Rejection Treatment

The USPTO published patent application US20260092113A1, filed by Bristol-Myers Squibb, covering methods for treating solid organ transplant rejection using CD28/OX40 bispecific antibodies. The application (No. 19237572) claims a multispecific binding protein with a VHH domain targeting CD28 and a VH/VL domain targeting OX40. Inventors include Rami Lissilaa, Benjamin Suratt, and Jessica Voss.

Treatment of Lung Cancer Using Anti-PD-1 Antibody Combination

The USPTO published Bristol-Myers Squibb Company's patent application (US20260092114A1) for a method of treating lung cancer using a combination of an anti-PD-1 antibody administered by infusion in under 60 minutes and optionally an anti-CTLA-4 antibody administered in under 90 minutes. The application was filed on September 29, 2025.

Anti-CTLA-4 antibodies with variant Fc regions

The USPTO published patent application US20260092115A1 for anti-CTLA-4 antibodies featuring variant Fc regions and methods of production and use. The application (No. 19407391) was filed December 3, 2025, by a team of 11 inventors including researchers from pharmaceutical companies. The invention relates to therapeutic antibodies modified to enhance effector functions through Fc region engineering.

B7H3/PDL1 Bispecific Antibody Cancer Therapeutic

The USPTO published patent application US20260092116A1 by DARTSBIO Pharmaceuticals Ltd. covering a B7H3/PDL1 bispecific antibody for cancer treatment. The invention comprises a monoclonal antibody targeting PDL1 linked to nano-antibodies targeting B7H3, designed to relieve T-cell inhibition while targeting tumor cells. The application was filed October 13, 2022, with six inventors.

Bladder Cancer Classification and Treatment Using Atezolizumab

The USPTO published patent application US20260092117A1 disclosing methods for classifying and treating bladder cancer (including locally advanced or metastatic urothelial cancer) using atezolizumab, a PD-1 axis binding antagonist. The application covers diagnostic methods, treatment regimens, compositions, kits, and articles of manufacture for bladder cancer classification and therapy. The application was filed on April 4, 2025.

Treatment of Cancer Using Anti-HLA-G/Anti-CD3 Bispecific Antibody and 4-1BB Agonist

The USPTO published patent application US20260092118A1 by Hoffmann-La Roche Inc., covering a method for treating cancer using an anti-HLA-G/anti-CD3 bispecific antibody in combination with a 4-1BB (CD137) agonist. The application (No. 19325175) was filed September 10, 2025, and lists Meher Majety, Carina Hage, and Johannes Sam as inventors. This publication represents an early-stage intellectual property filing for a bispecific antibody-based cancer therapy.

Anti-NRP2 Antibody Compositions and Methods for Treating NRP2-Associated Diseases

The USPTO published patent application US20260092122A1 for affinity-matured and humanized antibodies targeting human neuropilin-2 (NRP2) polypeptides. The application (No. 19293892, filed August 7, 2025) names six inventors and covers therapeutic compositions and methods for modulating NRP2 activity to treat NRP2-associated diseases, including cancer (A61P 35/04).

Multivalent FZD4, Wnt Co-receptor, and VEGF Binding Molecules

EyeBiotech Limited published US Patent Application US20260092125A1 for multivalent antibody binding molecules comprising FZD4 receptor binding, LRP5 co-receptor binding, and VEGF binding domains that activate the Wnt/β-catenin signaling pathway. The application covers the molecules, nucleic acids, vectors encoding them, and methods of use. Inventors include Paul E. Stephens, Michael John Davies, Yin Shan Eric Ng, Masahisa Handa, and Alexander V. Loktev. The application was filed September 4, 2025, and published April 2, 2026.

Chrysin Pinocembrin CAPE Composition for Neuroinflammation Prevention

The USPTO published patent application US20260091016A1 claiming a composition comprising chrysin, pinocembrin, and CAPE (caffeic acid phenethyl ester) for preventing or treating neuroinflammation and associated neuropsychiatric and neurological diseases. Application No. 18904297 was filed October 2, 2024. The composition is classified under CPC codes A61K 31/352, A61K 31/216, A61K 35/644, and A61P 25/28.

Patent for micheliolide compositions to increase muscle mass

USPTO published patent application US20260091019A1 by Korea Institute of Science and Technology for a pharmaceutical composition containing micheliolide as an active ingredient for increasing muscle mass, improving muscle function, or preventing or treating muscular disease. The application (No. 19302634) was filed August 18, 2025 and published April 2, 2026, listing 12 inventors including Myungsuk Kim and Choong-Gu Lee.

Treatments for Inflammation - Connexin Hemichannel Modulators

USPTO published patent application US20260091017A1 by inventors Shome, Mugisho, and Rupenthal for inflammation treatment compounds and methods using connexin hemichannel modulators, inflammasome modulators, and pannexin channel modulators. The application covers compositions for treating ocular and dermatological diseases characterized by inflammasome-mediated inflammation through systemic and topical administration. Application No. 19342361 filed September 26, 2025.

Panobinostat Combination Therapy for Cholangiocarcinoma Treatment

The USPTO published patent application US20260091021A1 covering combination therapies comprising panobinostat for treating cholangiocarcinoma. The application (No. 19413668, filed December 9, 2025) names seven inventors and claims pharmaceutical compositions combining panobinostat with cytotoxic agents.

Treatment of Acute Cannabinoid Overdose

USPTO published patent application US20260091020A1 for methods of treating acute cannabinoid intoxication and metrics for evaluating cannabis intoxication. Inventors are Joseph Fenton LAWLER, Daniel Pawel SCHNEEBERGER, and Kenneth C. CUNDY, with application filing date of September 25, 2023.

Anti-B7-H3 ADC Combined with ATR/ATM Inhibitor for Cancer Treatment

The USPTO published patent application US20260091123A1 by Daiichi Sankyo Company Limited covering a pharmaceutical composition and method of treatment combining an anti-B7-H3 antibody-drug conjugate with an ATR inhibitor or ATM inhibitor for cancer therapy. The application claims the drug-linker conjugate structure and treatment methods. Filing date was October 9, 2025.

Targeted Delivery System Using CD45+ Leukocyte Cells for Glioma Treatment

USPTO published patent application US20260091119A1 disclosing an isolated targeted delivery system using CD45+ leukocyte cells containing iron binding proteins complexed with therapeutic or diagnostic agents for glioma treatment. Inventors include Magdalena KRÓL and seven co-inventors. The application was filed on September 1, 2023.

Macrophage targeting drug conjugates with mannose linker

The USPTO published patent application US20260091117A1 for macrophage targeting drug conjugates developed by P.I.F. Entrepreneurs Ltd. The conjugates comprise a drug moiety, mannose moiety, and linker (hydrazone or oxime group) for targeted therapeutic delivery. Application No. 19411275 was filed December 7, 2025.

Coronavirus Vaccine Nucleic Acid LNP Patent

USPTO published CureVac SE's patent application (US20260091107A1) for nucleic acid sequences and compositions suitable for coronavirus vaccines, particularly COVID-19, delivered via lipid nanoparticle (LNP) technology. The application covers compositions, vaccines, first and second medical uses, and methods of treatment or prevention. Filed as Application No. 19317057 with priority date September 2, 2025.

BacPROTACs for Targeted Protein Degradation in Bacteria

Washington University published patent application US20260091118A1 for bivalent agents (BacPROTACs) designed for targeted protein degradation in mycobacteria and other bacteria, including methods for reducing antibiotic resistance. The application (No. 19312129, filed August 27, 2025) covers compositions and methods for treating antibiotic-resistant bacterial infections.

Janus antimicrobial nanoparticles embedded in polymers

USPTO published patent application US20260091127A1 for Janus antimicrobial nanoparticles with distinct hydrophobic and polycationic surfaces embedded in crosslinked polymers. The invention aims to enhance traditional antibiotics and reduce necessary dosages against multi-drug resistant bacteria. Application No. 19344327 was filed September 29, 2025, and published April 2, 2026.

Multifunctional drug delivery system for cancer treatment antibodies

USPTO published patent application US20260091125A1 for a multifunctional drug delivery system using inorganic core particles conjugated to antibodies for cancer treatment. The system delivers distinct immunoglobulins to cancerous cells and tissues outside the brain via four-linker architecture. Application filed January 12, 2023; granted Application No. 18865714.

Tick Immunity Compositions and Methods

USPTO published patent application US20260091095A1 by inventors Erol Fikrig and Sukanya Narasimhan for compositions and methods generating tick immunity. The application (No. 19320550) was filed September 5, 2025, and published April 2, 2026. The invention covers pharmaceutical compositions for tick immunity under CPC classifications A61K 39/0003, A61P 33/14, and related subclasses.